<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="6775">5-Aminosalicylic acid</z:chebi> (<z:chebi fb="0" ids="6775">5-ASA</z:chebi>), the active moiety of sulphasalazine (SASP), was given as a rectal enema to patients with mild to moderate distal <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> to determine the minimum effective dosage </plain></SENT>
<SENT sid="1" pm="."><plain>A double blind study was carried out using enemas containing 1, 2, or 4 g or <z:chebi fb="0" ids="6775">5-ASA</z:chebi> or placebo for a one month treatment period </plain></SENT>
<SENT sid="2" pm="."><plain>One hundred and thirteen patients with <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> attending our outpatient clinic volunteered to participate </plain></SENT>
<SENT sid="3" pm="."><plain>Clinical, sigmoidoscopic, and histological assessments were carried out at the beginning of the study and after 15 and 30 days of treatment </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients who received <z:chebi fb="0" ids="6775">5-ASA</z:chebi> enemas showed significantly better results than those who received a placebo enema (p less than 0.001) but no difference was detected among the patients receiving differing concentrations of <z:chebi fb="0" ids="6775">5-ASA</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>This study suggests that 1 g <z:chebi fb="0" ids="6775">5-ASA</z:chebi> (in a 100 ml enema) is a sufficient dosage for patients with a mild to moderate attack of <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> </plain></SENT>
</text></document>